Post Profile






Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify responders

The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumours were reported today at the ESMO 2016 Congress in Copenhagen. The novel compound uses messenger RNA (mRNA) in tumours to identify patients who will respond.
read more

share

Related Posts


Discovery of new target for breast cancer drugs

Health : Medical News Today

Scientists have identified higher levels of a receptor protein found on the surface of human breast tumour cells that may serve as a new drug target for the treatment of breast cancer. The results, which are published in EMBO Molecu...

Immunotherapy shows promising results in first, second line treatment of metastatic bladder cancer

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials.

70% of advanced cancer patients receive palliative care consultation at ESMO Designated Centers

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Seven out of ten patients with advanced cancer receive a palliative care consultation at ESMO Designated Centres of Integrated Oncology and Palliative Care, according to survey results.

Study confirms fibroblast growth factor receptors as targets for pancreatic cancer treatment

Health : Medical News Today

Proteins called fibroblast growth factor receptors (FGFRs) have been implicated in the development of pancreatic cancer, which remains difficult to treat. Researchers at Roswell Park Cancer Institute (RPCI) have now confirmed that F...

Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders

Health : EurekAlert: Health

(European Society for Medical Oncology) The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tu...

Comments


Copyright © 2016 Regator, LLC